Play all audios:
Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this
journal Receive 18 print issues and online access $259.00 per year only $14.39 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now
Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer
support REFERENCES * Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS
treat-and-extend protocol. Ophthalmology. 2015;122:146–52. Article PubMed Google Scholar * Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge B, et al. Ranibizumab or bevacizumab
for neovascular age-related macular degeneration according to the Lucentis Compared to Avastin Study treat-and-extend protocol: two-year results. Ophthalmology. 2016;123:51–9.
https://doi.org/10.1016/j.ophtha.2015.09.018 Article PubMed Google Scholar Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * UCL Institute of Ophthalmology, London, UK
Ishani Barai, Sobha Sivaprasad & Christin Henein Authors * Ishani Barai View author publications You can also search for this author inPubMed Google Scholar * Sobha Sivaprasad View
author publications You can also search for this author inPubMed Google Scholar * Christin Henein View author publications You can also search for this author inPubMed Google Scholar
CONTRIBUTIONS All authors equally contributed to the conceptualisation and creation of the visual abstract. CORRESPONDING AUTHOR Correspondence to Christin Henein. ETHICS DECLARATIONS
COMPETING INTERESTS S.S. reported receiving financial support from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Pharmaceuticals, Janssen
Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutics, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics, Sanofi. S.S. is Editor in Chief of _Eye_. I.B. and C.H. declare no
conflict of interest. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS
AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Barai, I., Sivaprasad, S. & Henein, C. Infographic: ranibizumab or bevacizumab treat & extend for
neovascular age-related macular degeneration (AMD): LUCAS trial. _Eye_ 39 (Suppl 1), 129–131 (2025). https://doi.org/10.1038/s41433-024-03339-z Download citation * Received: 18 March 2024 *
Revised: 06 August 2024 * Accepted: 06 September 2024 * Published: 18 September 2024 * Issue Date: February 2025 * DOI: https://doi.org/10.1038/s41433-024-03339-z SHARE THIS ARTICLE Anyone
you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the
Springer Nature SharedIt content-sharing initiative